MEDIUMBuilt-inPipeline
ersodetug lead clinical asset
“10-K Item 1: 'Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.'”
RZLT · Concentration risk · 10-K extracted
Rezolute (RZLT) concentration risks
Updated
The most significant concentration Rezolute discloses is ersodetug lead clinical asset, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Rezolute’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH0
MEDIUM2
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
small number of third-party raw material suppliers
“10-K Item 1A: 'We rely upon a small number of third-party suppliers for the manufacture of certain raw materials that are necessary to formulate our drug products'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-10-18Rezolute's concentrations are typical of a clinical-stage biotech, and they stack on one another. The first is pipeline concentration: its lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. This is a medium-share, structural exposure, because the company's value is tied to the clinical and regulatory outcome of one program. The second is a manufacturing dependency: the company relies upon a small number of third-party suppliers for the manufacture of certain raw materials that are necessary to formulate its drug products. It is also a medium-share exposure, with dependency character, and it matters because any supply interruption would fall on the same single program. The two are not independent. The pipeline concentration is the dominant, verdict-moving exposure, since a clinical setback would affect the entire investment case, whereas the supplier dependency is an operational risk that becomes material mainly if the lead asset advances toward commercialization. Neither is cushioned by diversification elsewhere in the business, based on the disclosed sources.
For the engine’s reasoning on RZLT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| RZLT● | Rezolute, Inc. | 0 | 2 | 0 | 2 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.